Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
Launched by POWER LIFE SCIENCES INC. · Sep 30, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into how women with recurrent ovarian cancer participate in studies about new treatments. The goal is to see if these new medicines are better than the ones we already have. By taking part in this research, patients can help doctors learn more about the disease and improve care for future patients.
To be eligible for this trial, participants need to be at least 18 years old and have a confirmed diagnosis of recurrent ovarian cancer. They should also be able to understand the study and give their consent to participate. The trial is not yet recruiting participants, but when it begins, those who join can expect to share their experiences and help advance medical knowledge in this area.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Aged ≥ 18 years old
- • Able to comprehend the investigational nature of the protocol and provide informed consent
- • Diagnosis of recurrent ovarian cancer
- Exclusion Criteria:
- • No diagnosis of recurrent ovarian cancer confirmed
- • Inability to perform regular electronic reporting
- • Patient does not understand, sign, and return consent form
About Power Life Sciences Inc.
Power Life Sciences Inc. is a forward-thinking clinical trial sponsor dedicated to advancing innovative therapeutic solutions across various medical disciplines. With a strong emphasis on scientific rigor and patient-centered approaches, the organization collaborates with leading researchers and healthcare professionals to design and execute clinical trials that prioritize safety, efficacy, and compliance. Power Life Sciences Inc. leverages cutting-edge technology and data analytics to streamline trial processes, enhance participant engagement, and accelerate the development of life-changing treatments, ultimately aiming to improve patient outcomes and contribute to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Michael B Gill
Study Director
Power Life Sciences Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported